Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Abstract:

:Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas to radiation. Gliomas express estramustine binding proteins, and cytotoxic concentrations of estramustine metabolites are found in gliomas after oral administration. Twenty three patients, aged 25-78, with new or recurrent high grade glioma were treated with estramustine and radiosurgery and/or radiotherapy. Patients with recurrent tumors were treated with estramustine and Gamma Knife stereotactic radiosurgery; eligible tumors were limited to 4 cm maximal diameter. Patients with newly diagnosed tumors were treated with estramustine and fractionated radiotherapy, with radiosurgery also performed if the tumor was less than 4 cm maximal diameter. Estramustine (16 mg/kg per day orally) was started three days prior to radiosurgery, or, if only radiotherapy was performed, on the first day of radiotherapy. Estramustine was continued until the completion of radiosurgery and/or radiotherapy (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of the 13 patients treated for newly diagnosed glioblastoma, median survival was 16 months with 38% 2-year survival. Of five patients treated for recurrent glioblastoma, survival was 3, 8, 9, 15, and 23 + months. Two patients with recurrent anaplastic astrocytoma survived for 24 and 48+ months. One patient with recurrent anaplastic mixed glioma survived 5+ months. Two patients with newly diagnosed anaplastic oligodendroglioma survived 20 and 42+ months. Four of the new glioblastoma patients developed deep vein thrombosis. The results of this pilot study indicate some benefit, and further investigation incorporating estramustine into clinical trials is suggested.

journal_name

J Neurooncol

authors

Landy H,Markoe A,Potter P,Lasalle G,Marini A,Savaraj N,Reis I,Heros D,Wangpaichitr M,Feun L

doi

10.1023/b:neon.0000021825.41221.b5

subject

Has Abstract

pub_date

2004-03-01 00:00:00

pages

215-20

issue

1-2

eissn

0167-594X

issn

1573-7373

journal_volume

67

pub_type

杂志文章
  • MGMT promoter methylation in non-neoplastic brain.

    abstract::O(6)-methylguanine-DNA-methyltransferase (MGMT) is mainly regulated by cytosine-guanine island promoter methylation that is believed to occur only in neoplastic tissue. The present study was undertaken to investigate whether methylation occurs also in non-neoplastic brains by collecting 45 non-neoplastic brains from a...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-014-1663-3

    authors: Hsu CY,Ho HL,Chang-Chien YC,Chang YW,Ho DM

    更新日期:2015-02-01 00:00:00

  • Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.

    abstract:BACKGROUND:A prospective Phase II study of CPT-11 in adult patients with recurrent supratentorial glioblastoma multiforme (GBM). METHODS:Forty patients (25 men, 15 women) ages 32-71 years (median 59), with recurrent GBM were treated. All patients had previously been treated with surgery and involved field radiotherapy...

    journal_title:Journal of neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1014532202188

    authors: Chamberlain MC

    更新日期:2002-01-01 00:00:00

  • Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.

    abstract::Anaplastic oligodendroglioma (AO) is an uncommon intracranial tumor and prognosis is poor. In this study, we assessed the factors affecting the prognosis of AO patients. Seventy AO patients were recruited from 2001 to 2006 in Shanghai Huashan Hospital of Fudan University; all were treated surgically. Kaplan-Meier surv...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s11060-010-0146-4

    authors: Yang LS,Huang FP,Zheng K,Zhang HS,Zhou X,Bao XH,Zheng JJ,Chang C,Zhou LF

    更新日期:2010-10-01 00:00:00

  • Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1.

    abstract:INTRODUCTION:Glioblastoma (GBM) is the most common primary brain cancer. The average survival time for the majority of patients is approximately 15 months after diagnosis. A major feature of GBM that contributes to its poor prognosis is its high invasiveness. Caveolae are plasma membrane subdomains that participate in ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-019-03161-8

    authors: Pu W,Nassar ZD,Khabbazi S,Xie N,McMahon KA,Parton RG,Riggins GJ,Harris JM,Parat MO

    更新日期:2019-06-01 00:00:00

  • Sex differences in length of survival with malignant astrocytoma, but not with glioblastoma.

    abstract::In a retrospective analysis based on a malignant glioma databank, we describe effects of age, sex and diagnosis upon survival in patients with malignant cerebral glioma with a pre-treatment Karnofsky-index of 60 or more. All patients had been treated with 55-60Gy radiotherapy and nitrosurea-based adjuvant chemotherapy...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1023/a:1011849411227

    authors: Diete S,Treuheit T,Dietzmann K,Schmidt U,Wallesch CW

    更新日期:2001-05-01 00:00:00

  • Gene expression profiling analysis reveals that DLG3 is down-regulated in glioblastoma.

    abstract::Glioblastoma multiforme (GBM) is the most malignant glioma. In the current study, 149 astrocytoma gene expression datasets were classified by prediction analysis of microarray. Strikingly, disks large homolog 3 (DLG3), a membrane-associated guanylate kinase-family gene, had the highest score in the GBM subset. DLG3 mR...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-013-1325-x

    authors: Liu Z,Niu Y,Xie M,Bu Y,Yao Z,Gao C

    更新日期:2014-02-01 00:00:00

  • Intravascular lymphomatosis (IL) in a child mimicking a posterior fossa tumor.

    abstract::Intravascular lymphomatosis (IL) is a rare entity only recently included in lymphoma classification, whose main feature is the exclusive or predominant growth of neoplastic cells within blood vessels. The vast majority of the patients affected by IL belong to the 7th or 8th decade of life and present with skin rash or...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1023/a:1006476701534

    authors: Massimino M,Giardini R,Cefalo G,Simonetti F,Pollo B,Giombini S,Tesoro-Tess JD,Ponzoni M,Patriarca C

    更新日期:2001-01-01 00:00:00

  • Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma.

    abstract::Death ligand-mediated apoptosis is a promising strategy of gene therapy for human malignant glioma. We here report that the infection of human malignant glioma cell lines with an adenoviral vector encoding full length human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Ad-Apo2L/TRAIL) results in...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1023/a:1021248329980

    authors: Naumann U,Waltereit R,Schulz JB,Weller M

    更新日期:2003-01-01 00:00:00

  • Brain tumor protocols in North America.

    abstract::A list of active investigative brain tumor protocols in North America is presented. The fact that there are 138 protocols (and certainly some have been missed) indicates the diversity and intensity of research into this difficult problem. The geographic diversity of institutions involved in brain tumor clinical trials...

    journal_title:Journal of neuro-oncology

    pub_type:

    doi:10.1007/BF01049979

    authors: Bernstein M,Rutka J

    更新日期:1993-09-01 00:00:00

  • Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.

    abstract::Treatment for anaplastic astrocytoma (AA) is controversial. To assess three primary treatment approaches, patients from a single institution were retrospectively evaluated. To represent modern treatment selection, patients diagnosed with AA from December 2003 to December 2009 were selected. Those with insufficient dat...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-013-1116-4

    authors: Shonka NA,Theeler B,Cahill D,Yung A,Smith L,Lei X,Gilbert MR

    更新日期:2013-06-01 00:00:00

  • A prospective evaluation of whole brain volume loss and neurocognitive decline following hippocampal-sparing prophylactic cranial irradiation for limited-stage small-cell lung cancer.

    abstract:INTRODUCTION:This study evaluated an association between whole brain volume loss and neurocognitive decline following prophylactic cranial irradiation (PCI) for limited-stage small-cell lung cancer (SCLC). METHODS:This was a secondary analysis of a prospective clinical trial that accrued patients at a single instituti...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-019-03235-7

    authors: Gui C,Chintalapati N,Hales RK,Voong KR,Sair HI,Grimm J,Duhon M,Kleinberg LR,Vannorsdall TD,Redmond KJ

    更新日期:2019-09-01 00:00:00

  • Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells.

    abstract::Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown potent and cancer-selective killing activity and drawn considerable attention as a promising therapy for cancer. Another promising cancer therapy is difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, which is oraly administ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-015-1799-9

    authors: Alexiou GA,Tsamis KI,Vartholomatos E,Peponi E,Tzima E,Tasiou I,Lykoudis E,Tsekeris P,Kyritsis AP

    更新日期:2015-06-01 00:00:00

  • Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors.

    abstract::A phase II trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m2/day by continuous 5 day intravenous infusion (3 mg/m2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/BF02427837

    authors: Feun LG,Savaraj N,Landy H,Levin H,Lampidis T

    更新日期:1990-10-01 00:00:00

  • Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation.

    abstract::High-grade gliomas release excitotoxic concentrations of glutamate which contributes to their malignant phenotype. To improve our understanding of the mechanisms by which glutamate enhances tumor growth and invasion, we examined alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-mediated signaling in glio...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-008-9552-2

    authors: de Groot JF,Piao Y,Lu L,Fuller GN,Yung WK

    更新日期:2008-06-01 00:00:00

  • Epigenetics and survivorship in pediatric brain tumor patients.

    abstract:INTRODUCTION:Brain tumors make up over a quarter of pediatric malignancies. Depending on the age of presentation and treatment, pediatric brain tumor survivors experience varying degrees of treatment induced morbidity and sequelae. Epigenetic mechanisms play a critical role in silencing of tumor suppressor genes and ac...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s11060-020-03535-3

    authors: Bhattacharya D,Pomeroy SL,Pomeranz Krummel DA,Sengupta S

    更新日期:2020-10-01 00:00:00

  • Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.

    abstract::In the context of bevacizumab therapy for the treatment of progressive malignant gliomas, it is currently unclear how different magnetic resonance imaging (MRI) sequences correlate with each other over time. The objective of this study was to determine if a reliable and predictable relationship over time exists betwee...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-010-0397-0

    authors: Thompson EM,Dosa E,Kraemer DF,Neuwelt EA

    更新日期:2011-06-01 00:00:00

  • Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology.

    abstract::The Coronavirus pandemic has created unprecedented strain on medical resources at health care institutions around the world. At many institutions, this has resulted in efforts to prioritize cases with an attempt to balance the acuity of medical needs with available resources. Here, we provide a framework for instituti...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-020-03488-7

    authors: Ramakrishna R,Zadeh G,Sheehan JP,Aghi MK

    更新日期:2020-05-01 00:00:00

  • Multifocal motor neuropathy with conduction block associated with metastatic lymphoma of the nervous system.

    abstract::Peripheral neuropathies occur in 5% of patients with Non-Hodgkin Lymphoma and represent the effects of therapy, direct compression or nerve infiltration by tumor, or paraneoplastic effects. Multifocal motor neuropathy with conduction block (MMNCB) is a rare demyelinating disorder of unknown etiology characterized by p...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-005-9060-6

    authors: Stern BV,Baehring JM,Kleopa KA,Hochberg FH

    更新日期:2006-05-01 00:00:00

  • Histopathological vascular investigation of the peritumoral brain zone of glioblastomas.

    abstract::To date, no histopathological vascular investigation focusing on peritumoral brain zone (PBZ) has been reported for glioblastoma. We analyzed 10 newly diagnosed cases of glioblastomas. For these PBZs, histopathological investigation was performed by hematoxylin-eosin (H&E) staining and immunohistochemistry was analyze...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-017-2648-9

    authors: Tamura R,Ohara K,Sasaki H,Morimoto Y,Yoshida K,Toda M

    更新日期:2018-01-01 00:00:00

  • Surgery of insular and paralimbic diffuse low-grade gliomas: technical considerations.

    abstract::Once considered a "no man's land" especially when invaded by a diffuse low grade glioma (DLGG), the insula remains to this day a surgical challenge. Surgery for insular DLGG involves consideration of its hidden location under the potentially eloquent operculae, the proximity to vascular tree and high density of functi...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s11060-016-2120-2

    authors: Michaud K,Duffau H

    更新日期:2016-11-01 00:00:00

  • Pre- and early postoperative GFAP serum levels in glioma and brain metastases.

    abstract:SUBJECT:To date there is no established tumor marker for the clinical follow-up of glioblastoma, WHO grade IV, (GBM) which constitutes the most frequent and malignant primary brain tumor. However, since there is promising data that the serum glial fibrillary acidic protein (sGFAP) may serve as a biomarker for glial bra...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-018-2898-1

    authors: Baumgarten P,Quick-Weller J,Gessler F,Wagner M,Tichy J,Forster MT,Foerch C,Seifert V,Mittelbronn M,Senft C

    更新日期:2018-09-01 00:00:00

  • Primitive neuroectodermal tumours (PNETs) located in the spinal canal; the relevance of classification as central or peripheral PNET : case report of a primary spinal PNET occurrence with a critical literature review.

    abstract::Intraspinal location of central PNET (cPNET) is very rare. We present a case, critically review all publications of primary intraspinal cPNET occurrence and discuss tendencies in clinical presentation. In several previous attempts to summarise, authors often confused cPNET with peripheral PNET (pPNET). cPNET and pPNET...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s11060-005-9006-z

    authors: Kampman WA,Kros JM,De Jong TH,Lequin MH

    更新日期:2006-03-01 00:00:00

  • Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.

    abstract::We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma. Pre-RT temozolomide was given for up to 6 cycles. RT with concurrent...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11060-015-1845-7

    authors: Vogelbaum MA,Hu C,Peereboom DM,Macdonald DR,Giannini C,Suh JH,Jenkins RB,Laack NN,Brachman DG,Shrieve DC,Souhami L,Mehta MP

    更新日期:2015-09-01 00:00:00

  • Evaluation of neo-angiogenesis in a case of chordoid meningioma.

    abstract::Chordoid is a rare variant of meningioma that displays a high recurrence rate. In this study we evaluated the immunohistochemical expression of factors that regulate the neo-angiogenesis process in a case of chordoid meningioma with an adverse clinical course. A high microvessel density (MVD), as well as high VEGF and...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-009-9942-0

    authors: Barresi V,Tuccari G

    更新日期:2009-12-01 00:00:00

  • Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.

    abstract::In earlier studies, we demonstrated that intratumoral infusions of alloreactive cytotoxic T lymphocytes (aCTL), sensitized to the major histocompatibility complex (MHC) antigens of the host, effectively retarded the intracranial growth of Fischer 9L gliosarcoma. We further demonstrated that continuous in vitro exposur...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/BF02700024

    authors: Paul DB,Read SB,Kulprathipanja NV,Gomez GG,Kleinschmidt-DeMasters BK,Schiltz PM,Kruse CA

    更新日期:2003-08-01 00:00:00

  • The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma.

    abstract::Improvements in imaging are increasing the detection of multiple lesions in the setting of glioblastoma. Occasionally distant non-enhancing lesions may be identified which have the appearances of a multicentric low-grade glioma. We aimed to determine the incidence, prognostic significance and diagnostic value of this ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11060-016-2193-y

    authors: Lasocki A,Gaillard F,Tacey MA,Drummond KJ,Stuckey SL

    更新日期:2016-09-01 00:00:00

  • Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells.

    abstract::Tanshinone IIA is a derivative of phenanthrene-quinone isolated from Danshen, a widely used Chinese herbal medicine. It has antioxidant properties, cytotoxic activities against multiple human cancer cells, inducing apoptosis and differentiation of some human cancer cells. The purpose of this study is to confirm its an...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-006-9242-x

    authors: Wang J,Wang X,Jiang S,Yuan S,Lin P,Zhang J,Lu Y,Wang Q,Xiong Z,Wu Y,Ren J,Yang H

    更新日期:2007-03-01 00:00:00

  • Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression.

    abstract::The leucine-rich repeats and immunoglobulin-like domains (LRIG) protein family is comprised of three integral membrane proteins: LRIG1, LRIG2, and LRIG3. LRIG1 is a negative regulator of growth factor signaling. The expression and subcellular localization of LRIG proteins have prognostic implications in primary brain ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-012-0856-x

    authors: Ghasimi S,Haapasalo H,Eray M,Korhonen K,Brännström T,Hedman H,Andersson U

    更新日期:2012-07-01 00:00:00

  • Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme.

    abstract:INTRODUCTION:Carmustine (BCNU)-impregnated biodegradable polymer wafers have been shown to prolong survival in patients with recurrent malignant glioma. Interferon alfa-2b (IFNalpha(2b)) has demonstrated antitumor activity against a number of cancers, but its use in glioma has been limited. The use of these agents in c...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-008-9660-z

    authors: Olson JJ,McKenzie E,Skurski-Martin M,Zhang Z,Brat D,Phuphanich S

    更新日期:2008-12-01 00:00:00

  • Intracranial melanotic schwannomas: a rare variant with unusual adherent features.

    abstract::Intracranial melanotic schwannomas (IMSch) are extremely rare nerve sheath tumors with features of Schwann cells that produce melanin. After a thorough review of the available literature since 1967, we report not only the 20th case of IMSch but a comprehensive modern-era analysis of radiographic and histological key-p...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-017-2653-z

    authors: Mahato D,Vivas-Buitrago T,Gassie K,Jentoft M,Tavanaiepour D,Quiñones-Hinojosa A

    更新日期:2018-01-01 00:00:00